These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27288807)

  • 1. Investigation of serum levels and tissue expression of two genes IGFBP-2 and IGFBP-3 act as potential biomarker for predicting the progression and survival in patients with glioblastoma multiforme.
    Abdolhoseinpour H; Mehrabi F; Shahraki K; Khoshnood RJ; Masoumi B; Yahaghi E; Goudarzi PK
    J Neurol Sci; 2016 Jul; 366():202-206. PubMed ID: 27288807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
    Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
    Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
    Lin Y; Jiang T; Zhou K; Xu L; Chen B; Li G; Qiu X; Jiang T; Zhang W; Song SW
    Neuro Oncol; 2009 Oct; 11(5):468-76. PubMed ID: 19164435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
    Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
    Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.
    Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V
    J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.
    Marucci G; Morandi L; Magrini E; Farnedi A; Franceschi E; Miglio R; Calò D; Pession A; Foschini MP; Eusebi V
    Virchows Arch; 2008 Dec; 453(6):599-609. PubMed ID: 18953566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic value of stem cell factor plasma level in glioblastoma multiforme patients.
    Kefayat A; Amouheidari A; Ghahremani F; Alirezaei Z
    Cancer Med; 2021 Aug; 10(15):5154-5162. PubMed ID: 34250760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines.
    Amoureux MC; Coulibaly B; Chinot O; Loundou A; Metellus P; Rougon G; Figarella-Branger D
    BMC Cancer; 2010 Mar; 10():91. PubMed ID: 20219118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor binding protein-2 regulates β-catenin signaling pathway in glioma cells and contributes to poor patient prognosis.
    Patil SS; Gokulnath P; Bashir M; Shwetha SD; Jaiswal J; Shastry AH; Arimappamagan A; Santosh V; Kondaiah P
    Neuro Oncol; 2016 Nov; 18(11):1487-1497. PubMed ID: 27044294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24.
    Fukushima T; Tezuka T; Shimomura T; Nakano S; Kataoka H
    J Biol Chem; 2007 Jun; 282(25):18634-18644. PubMed ID: 17475624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression patterns of insulin-like growth factor binding protein isoforms in medulloblastoma subtypes and clinical correlation.
    Narayan R; Shastry AH; Thota B; Sampath S; Thennarasu K; Arivazhagan A; Santosh V
    Pediatr Neurosurg; 2013; 49(6):325-30. PubMed ID: 25427587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor binding protein-2 and glucose-regulated protein 78 kDa: Potential biomarkers affect prognosis in IDH-wildtype glioblastoma patients.
    Harland AJ; Perks CM; White P; Kurian KM; Barber HR
    Cancer Med; 2023 Jul; 12(13):14426-14439. PubMed ID: 37212470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma IGFBP-2 levels after postoperative combined radiotherapy and chemotherapy predict prognosis in elderly glioblastoma patients.
    Han S; Meng L; Han S; Wang Y; Wu A
    PLoS One; 2014; 9(4):e93791. PubMed ID: 24690948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients.
    Yu JZ; Warycha MA; Christos PJ; Darvishian F; Yee H; Kaminio H; Berman RS; Shapiro RL; Buckley MT; Liebes LF; Pavlick AC; Polsky D; Brooks PC; Osman I
    J Transl Med; 2008 Nov; 6():70. PubMed ID: 19025658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade.
    Elmlinger MW; Deininger MH; Schuett BS; Meyermann R; Duffner F; Grote EH; Ranke MB
    Endocrinology; 2001 Apr; 142(4):1652-8. PubMed ID: 11250947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients.
    Hönikl LS; Lämmer F; Gempt J; Meyer B; Schlegel J; Delbridge C
    J Neurooncol; 2020 May; 147(3):567-575. PubMed ID: 32240464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.
    Vassilakopoulou M; Won M; Curran WJ; Souhami L; Prados MD; Langer CJ; Rimm DL; Hanna JA; Neumeister VM; Melian E; Diaz AZ; Atkins JN; Komarnicky LT; Schultz CJ; Howard SP; Zhang P; Dicker AP; Knisely JPS
    Oncology; 2021; 99(9):580-588. PubMed ID: 33957633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
    Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
    Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
    Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A
    Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patients.
    Cevik S; Kitis S; Evran S; Akkaya E; Tosuner Z; Hanimoglu H
    Niger J Clin Pract; 2018 Apr; 21(4):502-506. PubMed ID: 29607865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.